Panel: Unlocking the Full Potential of Biomarkers to Transform DDR Drug Development

• Exploring the evolving role of biomarkers in DDR therapy, from predictive tools to dynamic response monitors

• Evaluate the challenges of biomarker complexity, standardization, and clinical implementation

• Sharing cross-sector insights on integrating biomarkers into trial design, dosing strategies, and regulatory pathways

Speakers:

Michail Shipitsin

Vice President Biomarker Development

Acrivon Therapeutics

Luke Piggott

Director, Business Development

Debiopharm